EntreMed warned of possible NASDAQ delisting

EntreMed received notice that it will lose its NASDAQ listing unless it boosts its share price above $1 between now and Oct. 1. The NASDAQ exchange has warned the Rockville cancer drug company that …

Leave a Comment

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.